The Global Mycoplasma Testing Market size is expected to reach $1.9 billion by 2030, rising at a market growth of 11.5% CAGR during the forecast period.
The increasing awareness of the impact of mycoplasma contamination on cell culture research outcomes drives the growth of this testing in academic settings. Academic research institutes heavily rely on cell cultures for various studies, from basic cell biology to disease modeling and drug discovery. Consequently, the academic research institutes segment would acquire nearly 15 % of the total market share by 2030. Researchers prioritize implementing this testing to maintain the reliability of their experiments. Developing tissue engineering and three-dimensional (3D) cell culture models in academic research requires stringent quality control measures, including this testing. As researchers explore advanced cell culture techniques, the demand for these testing solutions that accommodate diverse models and experimental setups increases.
Advances in these testing methods, including rapid and high-throughput technology development, contribute to the market's growth. Technological innovations make testing more efficient, sensitive, and cost-effective, driving adoption across various industries. Mass spectrometry-based approaches, like matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), are gaining traction in mycoplasma identification. These techniques provide high-resolution and accurate identification of microbial species, including mycoplasma. Hence, the market is expanding significantly due to the technological advancements in testing methods. Additionally, the growth of the biopharmaceutical and biotechnology industries, characterized by the increasing production of therapeutic proteins, monoclonal antibodies, and other biologics, fuels the demand for this testing. The increasing production of biosimilars and biological products like approved biopharmaceuticals contributes to the demand for this testing. Thus, because of the rising biopharmaceutical and biotechnology industries, the market is anticipated to increase significantly.
Moreover, the COVID-19 pandemic intensified the global focus on vaccine development and biopharmaceutical production. With accelerated efforts to produce vaccines and therapeutic biologics, the demand for these testing solutions increased to ensure the quality and safety of these products. The urgency to develop and produce vaccines and therapeutics during the pandemic led to increased regulatory scrutiny. Regulatory agencies emphasized the importance of stringent quality control measures, including this testing, to ensure the safety and efficacy of emerging treatments. Thus, the COVID-19 pandemic had a moderate effect on the market.
However, Variations in results may result from the absence of standardized testing procedures among laboratories and regions. Achieving a universal standard for this testing is challenging due to the diversity of testing techniques and technologies used in different settings. Standardization may lead to complacency in continuously improving these testing methodologies. The assumption that a standardized method is universally applicable may discourage efforts to enhance testing technologies and protocols further. Hence, standardization of testing methods is a significant challenge that hampers the growth of market.
The increasing awareness of the impact of mycoplasma contamination on cell culture research outcomes drives the growth of this testing in academic settings. Academic research institutes heavily rely on cell cultures for various studies, from basic cell biology to disease modeling and drug discovery. Consequently, the academic research institutes segment would acquire nearly 15 % of the total market share by 2030. Researchers prioritize implementing this testing to maintain the reliability of their experiments. Developing tissue engineering and three-dimensional (3D) cell culture models in academic research requires stringent quality control measures, including this testing. As researchers explore advanced cell culture techniques, the demand for these testing solutions that accommodate diverse models and experimental setups increases.
Advances in these testing methods, including rapid and high-throughput technology development, contribute to the market's growth. Technological innovations make testing more efficient, sensitive, and cost-effective, driving adoption across various industries. Mass spectrometry-based approaches, like matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), are gaining traction in mycoplasma identification. These techniques provide high-resolution and accurate identification of microbial species, including mycoplasma. Hence, the market is expanding significantly due to the technological advancements in testing methods. Additionally, the growth of the biopharmaceutical and biotechnology industries, characterized by the increasing production of therapeutic proteins, monoclonal antibodies, and other biologics, fuels the demand for this testing. The increasing production of biosimilars and biological products like approved biopharmaceuticals contributes to the demand for this testing. Thus, because of the rising biopharmaceutical and biotechnology industries, the market is anticipated to increase significantly.
Moreover, the COVID-19 pandemic intensified the global focus on vaccine development and biopharmaceutical production. With accelerated efforts to produce vaccines and therapeutic biologics, the demand for these testing solutions increased to ensure the quality and safety of these products. The urgency to develop and produce vaccines and therapeutics during the pandemic led to increased regulatory scrutiny. Regulatory agencies emphasized the importance of stringent quality control measures, including this testing, to ensure the safety and efficacy of emerging treatments. Thus, the COVID-19 pandemic had a moderate effect on the market.
However, Variations in results may result from the absence of standardized testing procedures among laboratories and regions. Achieving a universal standard for this testing is challenging due to the diversity of testing techniques and technologies used in different settings. Standardization may lead to complacency in continuously improving these testing methodologies. The assumption that a standardized method is universally applicable may discourage efforts to enhance testing technologies and protocols further. Hence, standardization of testing methods is a significant challenge that hampers the growth of market.
By Technology Analysis
Based on technology, the market is classified into PCR, ELISA, microbial culture techniques, and enzymatic methods. The microbial culture techniques segment acquired a substantial revenue share in the market in 2022. Culturing mycoplasma isolates allows species identification, allowing laboratories to determine the specific types of mycoplasma present. This information can be valuable for understanding the nature of contamination and tailoring appropriate responses. Microbial culture techniques enable the testing of viable mycoplasma organisms, providing information on their ability to replicate and cause harm to cell cultures or biopharmaceutical products. This aspect is crucial for understanding the potential impact of contamination on production processes.By Application Analysis
On the basis of application, the market is divided into cell line testing, virus testing, end of production cells testing, and others. The virus testing segment garnered a significant revenue share in the market in 2022. Virus testing, alongside this testing, helps prevent cross-contamination in shared laboratory spaces and manufacturing facilities. The risk of cross-contamination between different cell lines or production batches is a concern that both types of testing address to maintain the integrity of biological products. Thorough virus and this testing helps to build public trust in the safety and efficacy of pharmaceutical and biopharmaceutical products. Ensuring that these products are free from harmful contaminants is paramount for the safety of patients and consumers.
By End User Analysis
By end user, the market is segmented into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others. The contract research organizations segment recorded a remarkable revenue share in the market in 2022. Contract research organizations (CROs) conduct preclinical and clinical studies for pharmaceutical and biotechnology companies. In these studies, this testing is essential to ensure the integrity of cell cultures and prevent contamination that can affect the reliability of study outcomes. CROs are early adopters of technological advancements in these testing methods. Their commitment to staying at the forefront of testing technologies drives the adoption of innovative and efficient mycoplasma detection methods.By Product & Service Analysis
By product & services, the market is categorized into instruments, kits & reagents, and services. The instruments segment covered a considerable revenue share in the market in 2022. Polymerase chain reaction (PCR) machines are widely used in this testing for amplifying and detecting specific DNA sequences. PCR-based assays are highly sensitive and specific, allowing for the rapid and accurate identification of mycoplasma DNA in samples. Microscopes, including fluorescent microscopy systems, are used to observe mycoplasma contamination in cell cultures directly. Fluorescent dyes are applied to label mycoplasma cells, making them visible under a microscope. This method allows for quick and direct visualization of contamination.By Regional Analysis
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. The biopharmaceutical industry in North America strongly emphasizes maintaining high manufacturing standards. Academic and research institutions in North America are actively involved in cell culture research, ranging from basic cell biology to advanced applications in biotechnology. The region is an early adopter of advanced testing technologies, including rapid and high-throughput methods for mycoplasma detection.List of Key Companies Profiled
- Charles River Laboratories International, Inc.
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific SE
- Lonza Group Ltd.
- Bio-Rad Laboratories, Inc.
- InvivoGen SAS
- Asahi Kasei Corporation
- F.Hoffmann-La Roche Ltd.
- Norgen Biotek Corp.
- PromoCell GmbH
Market Report Segmentation
By Product & Service- Kits & Reagents
- Instruments
- Services
- PCR
- ELISA
- Microbial Culture Techniques
- Enzymatic Methods
- Cell Line Testing
- Virus Testing
- End of Production Cells Testing
- Others
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutes
- Cell Banks
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Mycoplasma Testing Market by Product & Service
Chapter 5. Global Mycoplasma Testing Market by Technology
Chapter 6. Global Mycoplasma Testing Market by Application
Chapter 7. Global Mycoplasma Testing Market by End User
Chapter 8. Global Mycoplasma Testing Market by Region
Chapter 9. Company Profiles
Companies Mentioned
- Charles River Laboratories International, Inc.
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific SE
- Lonza Group Ltd.
- Bio-Rad Laboratories, Inc.
- InvivoGen SAS
- Asahi Kasei Corporation
- F. Hoffmann-La Roche Ltd.
- Norgen Biotek Corp.
- PromoCell GmbH
Methodology
LOADING...
